Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Exclusion Criteria

• •Subjects who have met DSMV-IV-TR criteria for substance dependence within the past 180 days.
• •Subjects who use more than one antipsychotic medication at screening.
• •Use of any CYP2D6 and CYP3A4 inhibitors, or CYP3A4 inducers within 14 days prior to dosing and for the duration of the trial.
• •Subjects who participated in any clinical trial involving a psychotropic medication within 1 month prior to enrollment.
• •Subjects currently in an acute relapse of schizophrenia.
• •Subjects with a current DSMV-IV-TR diagnosis other than schizophrenia.
• •Subjects who are considered treatment-resistant to antipsychotic medications.